We've just published our third quarter financial results and business updates- read more here: buff.ly/3NWjDH2 $CYAD

Today we are providing an update on our strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property. Learn more about this announcement here: bit.ly/3Wy5FxV

Interested in knowing more about our new strategy and the technologies and platform for #celltherapies we are developing at Celyad Oncology? Take a look at our updated corporate slide deck for more information! It's available here: bit.ly/3wSWihL

We have just published our fourth quarter 2022 business update and 2023 outlook! Take a look at it here: bit.ly/3DD1k5I. Celyad Oncology

We are delighted to share that we've just published the results from our THINK dose-escalation study in The Lancet Haematology! Read the full press release here: celyad.com/?p=7884 Celyad Oncology #publication #trial

We have just released our Letter to Shareholders ! Read it here: bit.ly/3ZbNQGC Nous venons de publier notre lettre aux Actionnaires! Vous pouvez la lire ici: bit.ly/3IDjkhN Celyad Oncology

Today we announce non-cash impairment of our goodwill and intangible oncology assets. Read the full press release here: celyad.com/?p=7980

Stay tuned!! Celyad Oncology will report full year 2022 financial and operating results on March 23 and host a conference call on March 24. Full details in the press release and conference here: celyad.com/?p=8023

Today we report full year 2022 financial results and recent business highlights. Check our press release here: celyad.com/?p=8052. Don't forget to join us for our conference call at 1 pm CET /8 am ET! $CYAD

We are so pleased to announce that Celyad Oncology has appointed Georges Rawadi as its new CEO! Georges has over 20 years of experience in pharma/biotech, but also knows Celyad quite well as he spent four years with us as VP BD & IP. See our PR here: celyad.com/?p=8060

Découvrez l'interview de notre CEO et Responsable communication scientifique par Laurent Grassin sur le plateau de l'Actu Bourse --> boursorama.com/videos/actuali…

Our senior scientist, Matteo Rossi, presented yesterday recent advances on our shRNA multiplexing platform at the 7th World Oncology Cell Therapy Congress  #WOCTCongress in Boston, where he highlighted versatility and adaptability of this technology. Congrats Matteo!

Our team is attending the Immuno-oncology summit Europe 2023 in London, UK on June 20-22 and our lead scientist Jennifer Bolsée will provide an update on our NKG2D-based multi-specific CAR T-cells. Come to attend to her talk! cutt.ly/WwwLpAms #IOSummitUK #cartcelltherapy

Onze intellectuele eigendom heeft een enorm potentieel voor het bedrijf! Lees het interview van onze CEO tijd.be/connect/pharma…

Notre propriété intellectuelle a un potentiel énorme pour notre Société. Lisez l'interview de notre CEO 👉🏻 lecho.be/connect/pharma…

We are excited to announce we have received EUR 9.8m in private placement commitments from our historical shareholders ! Read the full press release here : celyad.com/2023/08/24/cel…

Our team will take part at the 4th International Conference on Lymphocyte Engineering (#ICLE23) in Munich from Sep 12th to Sep 14th. If you are attending the conference, do not hesitate to discuss with them and in front of our posters (#125 and #135)!! lymphocyte.kenes.com/welcome-to-icl…

We are pleased to announce that the paper demonstrating the efficiency and versatility of our shRNA-based platform to knock-down multiple target genes was just accepted for publication in Molecular Therapy - Nucleic acids! 👉 rb.gy/84uji Congratulations to the team!!

Our latest review was just published in Cells! This review discusses the current state of allogeneic CAR-T cell therapy with regards to the different technologies that can be used to get off-the-shelf allogeneic CAR-Ts. Take a look at it here: 👇 MDPI

This #ImmunoOnco24 Poster pitch video is by Jennifer Bolsée Celyad Oncology. Her data show that the #NKG2D-based tandem CAR is a promising strategy to overcome antigen escape and enhance anti-tumor efficacy in both hematological and solid #tumors. 🚀 #CancerResearch #Immunotherapy